

Curriculum Vitae

Last name, First name: De Jong, Wilhelmus (Wim)

Gender: Male

Nationality: Dutch

Overall Scientific Expertise:

Wim H. De Jong, DVM, PhD has graduated as veterinarian at Utrecht University, the Netherlands in 1978 and is registered as specialist in Experimental Pathobiology, and Toxicological Pathology. He started his career as scientist in experimental oncology studying immunotherapy and drug targeting in animal tumor models, changed to vaccine control and next to safety evaluation of xenobiotics, medical devices and nanomaterials. He is involved in the safety evaluation and risk assessment of xenobiotics, biomaterials/medical devices and nanomaterials, and research in development of alternative methods for safety evaluation. He is/has been a member of various national and international advisory committees and is member of the editorial board and reviewer for several scientific journals. He retired in 2019 as senior scientist from the National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Professional Experience

Years employed from – to	Title of position	Employer – name and location	Areas of professional specialisation [▲]
1993-2019	Senior scientist (retired)	Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.	Toxicologic pathology, Safety evaluation medical devices, Nanotoxicology, Immunotoxicology, Nanomaterial Toxicokinetics, Risk assessment.
1990-1992	Senior scientist	Laboratory for Control of Biological Products (RIVM)	Safety and efficacy evaluation paediatric vaccines
1985-1990	Research scientist	Laboratory of Pathology (RIVM)	Immunotherapy and chemotherapy of cancer, drug delivery.
1978-1985	Research fellow	Dutch National Cancer Foundation, Amsterdam, The Netherlands	Immunotherapy of cancer, experimental oncology

Educational Background

Year	Degree awarded	Educational Institution – name and location	Areas of educational specialisation*
1971-1978	DVM	University of Utrecht, Utrecht, The Netherlands	Veterinary Medicine
1985	PhD	University Utrecht, Utrecht, The Netherlands	PhD in Veterinary Medicine

--	--	--	--

Memberships in Scientific Advisory Bodies/Committees/Panels (if any):

1993- 2019. Member of several working groups of ISO/CEN TC 194 “Biological and Clinical Evaluation of Medical Devices”, and since 2003 chairman of the WG “Irritation and sensitisation” and co-chair of the recently (2014) established WG “nanomaterials in medical devices”.

1997 – 2003. Member and vice chair of the Scientific Committee on Medicinal Products and Medical Devices, DG Health and Consumer Protection, EC, Brussels, Belgium.

2001 - 2019. Chairman of CEN TC 206 Biological Evaluation of Medical Devices.

2004- 2013 Vice chair of the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) for which he was both chairman and member of various working groups.

2007- 2019 Member of ISO TC 229 Nanotechnology, WG3 Health Safety and the Environment.

2017 – present Member of the Scientific Committee on Health, Environmental and Emerging Risks, DG Health and Food Safety, EC, Brussels, Belgium.

Memberships in Learned Societies (if any):

Dutch Society of Immunology, Dutch Society of Pathology, Dutch Society of Biomaterials and Tissue Engineering, Dutch Society of Toxicology.

Memberships in Editorial Boards (if any):

FEMS Immunology and Medical Microbiology (1993-1996), Biomaterials (2002 – present), Expert Reviews of Medical Devices (2004- 2021), Particle Fibre Toxicology (2011-present), Nanotoxicology (2015-present).

List of Publications:

The research conducted resulted in more than 180 publications in peer reviewed international journals and several book chapters. He was guest editor for a special issue of Methods.

“Animal models in immunotoxicology. Methods 41, 1-1, 2007”, and a special issue of Toxicology In Vitro on the use of reconstructed human epidermis (RhE) model for irritation testing of medical devices in 2018 (Toxicol In Vitro 50, 2018).

Specific publications:

De Jong WH, Jennen D, Keizers PHJ, Hodemaekers HM, Vermeulen JP, Bakker F, Schwillens P, Van Herwijnen, M, Jetten M. Kleinjans JCS, Geertsma RE, Vandebriel RJ. Evaluation of Adverse Effects of Resorbable Hyaluronic Acid Fillers: Determination of Macrophage Responses. Int. J. Mol. Sci. 2022, 23, 7275.

Åslund AKO, Vandebriel RJ, Caputo F, De Jong WH, Delmaar C, Hyldbakk A, Rustique E, Schmid R, Snipstad S, Texier I, Vernstad K, Borgos SEF. A comparative biodistribution study of polymeric and lipid-based nanoparticles. Drug Delivery and Translational Research. DDTR 2022

De Jong WH, Geertsma RE, Bochar G. Regulatory safety evaluation of nanomedical products: key issues to refine. Drug Deliv. and Transl. Res. (2022).

De Jong Wim H, Demosthenes Panagiotakos, Ana Proykova, Theodoros Samaras, Mark W. Clemens, Daphne De Jong, Ingrid Hopper, Hinne A. Rakhorst, Fabio Santanelli di Pompeo, Suzanne D. Turner, on behalf of SCHEER. Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: Report of the scientific committee on health, emerging and environmental risks (SCHEER). Regulatory Toxicology and Pharmacology 125 (2021) 104982.

De Jong WH, Carraway JW, Geertsma RE. In vivo and in vitro testing for the biological evaluation of biomaterials and medical devices. In; Boutrand JP (editor) Biocompatibility and performance of medical devices. 2nd Edition, Woodhead Publishing Ltd, Cambridge, UK. 2020, pp 123-166.

De Jong WH, Carraway JW, Liu C, Fan C, Liu J, Turley AP, Rollins TS, Coleman KP. The suitability of reconstructed human epidermis models for medical device irritation assessment: A comparison of In Vitro and In Vivo testing results. *Toxicol In Vitro*. 69, 2020 December :104995.

De Jong WH, Coleman KP, Blaauboer BJ. Reconstructed human epidermis models for irritant testing of medical devices. *Toxicol In Vitro*. 2018 Aug;50:399-400.

Hougaard KS, Campagnolo L, Chavatte-Palmerc P, Tarrade A, Rousseau-Ralliard D, Valentino S, Park MVDZ, De Jong WH, Wolterink G, Piersma AH, Ross BL, Hutchison GR, Stilund Hansen J, Vogel U, Jackson P, Slama R, Pietrojusti A, Cassee FR. A perspective on the developmental toxicity of inhaled nanoparticles. *Reproductive Toxicology* 56, 118-140, 2015.

Van Kesteren PCE, Cubadda F, Bouwmeester H, Van Eijkeren JCH, Dekkers S, De Jong WH, Oomen AG. Novel insights into the risk assessment of the nanomaterial synthetic amorphous silica, additive E551, in food. *Nanotoxicology*, 9, 442-452, 2015. Early on line 1-10, July 2014.

Geraets L, Oomen AG, Krystek P, Jacobsen NR, Wallin H, Laurentie M, Verharen HW, Brandon EFA, De Jong WH. Tissue distribution and elimination after oral and intravenous administration of different titanium dioxide nanoparticles in rats. *Part Fibre Toxicol* 2014:11:30.

Krystek P, Tentschert J, Nia Y, Trouillier B, Noël L, Goetz ME, Papin A, Luch A, Guérin T, De Jong WH. Method development and inter-laboratory comparison about the determination of titanium from titanium dioxide nanoparticles in tissues by inductively coupled plasma mass spectrometry. *Anal Bioanal Chem* 406, 3853-3861, 2014.

De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. *Int J Nanomedicine*, 3, 133-149, 2008.